Latest studies
- Active not recruitingPHASE2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
This study is testing a new medicine, Selinexor, for people in the UK with a type of cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has come back or not responded to previous treatments. It aims to see if Selinexor can help when other options haven't worked.
Diffuse Large B-cell LymphomaPoland - Active not recruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
This study is looking into a new treatment called prasinezumab for people in the early stages of Parkinson's disease. Researchers want to see if it's safe and helps improve symptoms. Participants will either receive the new medicine or a dummy treatment, called a placebo.
Parkinsons DiseasePoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with cerebral palsy
This study is testing a medicine called NT 201 (also known as Xeomin) for children and teenagers with cerebral palsy who have stiff leg muscles. It aims to see if the medicine helps reduce the stiffness and improve movement, compared to a dummy treatment.
Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma
This study is looking at a new way to treat follicular lymphoma, a type of cancer. It compares a drug called Ibrutinib with a standard treatment, Rituximab. The aim is to see if adding Ibrutinib helps people live longer without their cancer getting worse.
Follicular LymphomaPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b Multicenter, Randomized, Double-blind, Placebo-controlled Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-81241459 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis
This study is looking into a new medicine, JNJ-81241459, for people with moderate to severe plaque psoriasis. We want to see how well different doses work to clear up skin patches and if it's safe. It's a key step in developing new treatments.
Plaque PsoriasisPoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Clinical Trial to Compare Efficacy, Safety, Tolerability and Immunogenicity of RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration
This study is looking into a new treatment, RBS-001, for a specific eye condition called wet age-related macular degeneration (wet AMD). It compares RBS-001 with an existing treatment, Eylea, to see if it works as well or better, and if it's safe for patients.
Neovascular age-related macular degeneration (nAMD)Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 14-Week Phase 2b, RandomizEd, Double-BLind, Dose-Ranging Study to Determine the PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts with Moderate to Severe Ulcerative Colitis or Crohn’s Disease (RELIEVE UCCD)
This study is testing a new medicine called TEV-48574 for adults with moderate to severe Crohn's disease or ulcerative colitis. It aims to see how well it works, if it's safe, and how the body handles it, comparing it to a dummy medicine.
Crohn’s disease, Ulcerative colitisPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction
This study is testing a new medicine, Tovinontrine, for people with a type of heart failure where the heart struggles to pump blood effectively. It aims to see if different doses are safe and if the medicine helps improve heart health over 12 weeks.
Heart failure (HF) with reduced ejection fraction (HFrEF)Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants with Relapsing Multiple Sclerosis
This study is looking into a new medicine, LY3541860, for people with relapsing multiple sclerosis (RMS). Researchers want to see if it can reduce the number of new spots on the brain (lesions) compared to a dummy treatment (placebo).
Relapsing Multiple SclerosisPoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis - EFC17559 / COAST1
This study is testing a new medicine, amlitelimab, for moderate-to-severe eczema in people aged 12 and older. It aims to see how well it clears up skin and reduces itching compared to a dummy treatment, given as an injection.
Dermatitis atopicPoland - Recruiting
SMILE: Supporting mental health in young people: integrated methodology for clinical decisions and evidence-based interventions
The SMILE study helps young people (10-24) with anxiety or depression. It uses a fun online game and activities to build resilience and improve mental health. The study runs from February 2025 to July 2026 across seven countries, including the UK.
Depression and anxiety in children and young peoplePoland - Ongoing, recruitingPhase II and Phase III (Integrated)
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis.
This study is testing a new medicine called Belapectin. It's for people with liver scarring (cirrhosis) from NAFLD, to see if it can stop a serious problem called oesophageal varices from forming. Researchers want to know if it's safe and if it works better than a dummy medicine.
Esophageal Varices in NASH CirrhosisPoland - RecruitingPHASE3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
This study looks at new ways to treat multiple myeloma. Researchers are testing a drug called elranatamab, alone and with daratumumab, against a standard treatment. The aim is to find better and safer treatments for people who have tried other medicines.
Multiple MyelomaPoland - Active not recruitingPHASE2, PHASE3
International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma
This study looks at new ways to treat medulloblastoma, a type of brain tumour, in children and young people. It aims to find the best treatments based on the tumour's specific characteristics, hoping to improve the chances of recovery with fewer side effects.
Brain TumorsPoland - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer
This study is testing new treatments for advanced non-small cell lung cancer. It combines a new medicine, vudalimab, or an existing one, pembrolizumab, with chemotherapy. Doctors will be looking at how safe and effective these combinations are for patients.
Advanced Non-small Cell Lung CancerPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis
This study is testing a new medicine, Fipaxalparant, for a lung condition called Idiopathic Pulmonary Fibrosis (IPF). Researchers want to see if it's safe and helps improve lung function over one to two years compared to a dummy pill.
Idiopathic Pulmonary FibrosisPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
An adaptive, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of RL-007 in the treatment of cognitive impairment associated with schizophrenia (CIAS)
This study is looking into a new medication called RL-007 to help people with schizophrenia improve their thinking, learning, and memory skills. It's a key step to see if RL-007 is safe and effective.
Cognitive disorder, SchizophreniaPoland - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mRNA-3745 in participants with glycogen storage disease type 1a (GSD1a), followed by an open-label extension
This study is testing a new medicine, mRNA-3745, for Glycogen Storage Disease Type 1a (GSD1a). It's looking at how safe it is, how well people tolerate it, and how it works in the body, starting with low doses and gradually increasing them.
Glycogen storage disease type 1a (GSD1a)Poland - Recruiting
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
This study looks at how well a medicine called Atezolizumab works and how happy people are with it when used for lung cancer or a type of liver cancer in normal NHS care. It also checks for side effects.
Lung Cancer, Hepatocellular CarcinomaPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the efficacy and safety of daxdilimab subcutaneous injection in reducing disease activity in adult participants with moderate-to-severe primary discoid lupus erythematosus.
This study is looking into a new medication called daxdilimab for adults with a type of lupus called discoid lupus erythematosus. Researchers want to see if this medicine can improve skin symptoms and if it's safe to use compared to a dummy treatment.
Primary Discoid Lupus ErythematosusPoland - Recruiting
The Epithelioid Hemangioendothelioma Registry of the European Reference Network on Rare Adult Solid Cancers (EURACAN)
This registry tracks new adult cases of a rare cancer called Epithelioid Hemangioendothelioma (EHE). It aims to better understand the disease, its progression, and how different treatments work, by collecting information from patients across Europe and the UK.
Epithelioid HemangioendotheliomaSarcoma,Soft TissuePoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
Effects of NNC0194-0499 alone and in combination with semaglutide, of semaglutide alone, and of cagrilintide alone and in combination with semaglutide on liver damage and alcohol use in people with alcohol-related liver disease
This study is testing different new medicines, alone or in combination, to see if they can help improve liver damage and reduce alcohol use in people with liver problems caused by alcohol. One of the medicines is similar to a type already used for diabetes.
alcohol-related liver diseasePoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction
This study is testing a new medicine, Tovinontrine, for people with a type of chronic heart failure. It aims to see if the medicine is safe and if it can improve how the heart works according to blood tests, compared to a dummy pill.
chronic heart failurePoland - AuthorisedTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated with Dupilumab.
This study is testing a new medicine, eblasakimab, for adults with moderate to severe eczema (atopic dermatitis) who have already tried a medicine called dupilumab. Researchers want to see if it helps improve their skin and is safe.
Atopic DermatitisPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called Efavaleukin Alfa for people with moderate to severe Ulcerative Colitis. We want to see if it's safe and helps people feel better and get their condition under control within 12 weeks.
Ulcerative Colitis (UC)Poland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
This study is looking at a new treatment for stomach cancer and cancer where the food pipe joins the stomach. It's comparing a drug called pembrolizumab combined with chemotherapy against chemotherapy alone, to see if it helps patients live longer and stops the cancer from coming back.
Gastric and gastroesophageal junction (GEJ) adenocarcinomaPoland - Active not recruitingPHASE2, PHASE3
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
This study looks at a new drug, efgartigimod PH20 SC, for adults with active idiopathic inflammatory myopathy (IIM), a condition causing muscle weakness and inflammation. It compares the drug to a dummy treatment to see if it helps improve muscle strength and overall well-being.
Active Idiopathic Inflammatory MyopathyMyositisDermatomyositisPolymyositisPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase II, randomized, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatment.
This study looks at a new medicine called cabozantinib for young people with a type of bone cancer called osteosarcoma. It compares cabozantinib plus supportive care with supportive care alone to see if it helps stop the cancer from growing.
Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults, OsteosarcomaPoland - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
This study is testing a new drug, TAK-676, for adults with advanced solid cancers. It aims to see if TAK-676 is safe, how well it's tolerated, and how it works, both alone and with another cancer drug called Pembrolizumab (Keytruda).
Solid NeoplasmPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma
This study looks at a new drug, Calquence, for adults with a type of blood cancer called Mantle Cell Lymphoma. Researchers want to see how many people respond to the treatment and how safe it is.
Mantle Cell LymphomaPoland - Ongoing, recruitingTherapeutic use (Phase IV)
Adjustable brodalumab dosage regimen compared with standard brodalumab treatment for 52 weeks in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight; ADJUST - Phase 4 – efficacy, A randomised, double-blind, controlled, parallel group, multi-centre trial
This study compares a flexible dose of Brodalumab, a psoriasis treatment, with its usual dose for people with moderate to severe plaque psoriasis who weigh 120 kg or more. It aims to see if the adjustable dose works better at clearing skin.
Moderate-to-severe plaque psoriasis and a body weight ≥120 kg.Poland - Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in combination with Atezolizumab plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab plus Pemetrexed and Carboplatin/Cisplatin in Patients with previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer
This study looks at new drug combinations for advanced non-small cell lung cancer. It compares two treatments, one with a new drug called tiragolumab, to see which works best at shrinking tumours, stopping cancer growth, and helping people live longer and have a better quality of life.
Non-squamous non-small cell lung cancer (NSCLC)Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
C4221023 - A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI−PD-1 THERAPY
This study is looking at new drug combinations for people with a certain type of advanced melanoma that has not responded to previous treatment. It compares two groups of medicines to see which works better at shrinking the cancer.
Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanomaPoland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Abrocitinib in Subjects with Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
This study is looking at a new medicine called Cibinqo for people with long-lasting, moderate to severe hand eczema that hasn't improved with other treatments. It aims to see if the medicine is safe and effective in reducing symptoms.
Moderate to severe chronic hand eczemaPoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)
This study is looking at the long-term safety of a new medicine called Iclepertin for people with schizophrenia. It's for those who have already taken part in earlier studies of this medicine. We want to see how safe it is over a longer period.
SchizophreniaPoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
This study is looking at a new way to treat AL amyloidosis, a rare condition where unhealthy proteins build up in your body. It compares a new drug called daratumumab with existing treatments to see if it works better and is safe for people newly diagnosed with the condition.
AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)Poland - Active not recruiting
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This study looks at how a cancer drug called atezolizumab works in real patients. Researchers want to see its effects and safety under normal hospital care, for different types of cancer it's approved for.
Urothelial CarcinomaNon-Small Cell Lung CancerSmall Cell Lung CancerHepatocellular CarcinomaPoland - RecruitingPHASE1
A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
This study is looking at a new medicine called Inno8 for people with haemophilia A. Its main goal is to check how different amounts of the medicine work and if it's safe. It's a short study lasting about 11 weeks.
Haemophilia APoland - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
Cardiovascular Disease and Lipoprotein(a)Poland - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
This study looks at a new drug, Sacituzumab Govitecan, for advanced breast cancer. It compares it to standard treatments to see if it can slow cancer growth or spread, helping people live longer and healthier lives.
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast CancerPoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
58-week Open-Label Trial of Tavapadon in Parkinson’s Disease (Tempo-4 Trial)
This study is looking at a new medication called Tavapadon for people with Parkinson's disease. Researchers want to see if it's safe and how well it helps with symptoms over 58 weeks. It's a Phase 3 trial, meaning it's a big step towards potentially becoming a new treatment.
Parkinson's diseasePoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Subjects with Active Psoriatic Arthritis II (INSPIRE 2)
This study is testing a new medicine, Ilumetri, for adults with active psoriatic arthritis who haven’t used similar medicines before. Researchers want to see if it helps reduce symptoms like joint pain and swelling, and if it’s safe to use. Half the people will get the medicine, and half will get a dummy injection.
Psoriatic ArthritisPoland - RecruitingPHASE3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
This study looks at a new medicine called zilebesiran for people with high blood pressure that isn't well controlled, especially if they also have heart problems or are at high risk of developing them. The aim is to see if zilebesiran can reduce serious heart-related events like heart attacks or strokes.
High Risk Cardiovascular DiseaseHypertensionHigh Cardiovascular RiskPoland - Active not recruitingPHASE2, PHASE3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
This study investigates an injection called litifilimab for adults with active lupus that mainly affects the skin, known as cutaneous lupus erythematosus (CLE). Researchers want to see if it helps reduce skin symptoms and is safe, especially for those whose current treatments aren't working well.
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus ErythematosusPoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) KEYNOTE-091
This study looks at a drug called Keytruda after surgery for a type of lung cancer. It aims to see if Keytruda can stop the cancer from coming back for longer than a dummy treatment in patients with non-small cell lung cancer, especially those with certain cancer markers.
Stage IB (T ≥ 4 cm), II and IIIA NSCLCPoland - Ongoing, recruitingTherapeutic use (Phase IV)
Efficacy, safety, tolerability and quality of life of ongoing individually optimized lipid-lowering therapy with or without inclisiran (KJX839) – a randomized, placebo-controlled, double-blind multicenter phase IV study in participants with hypercholesterolemia
This study is looking at a new way to lower 'bad' cholesterol (hypercholesterolemia). It compares a new medicine called Inclisiran with usual treatments, to see if it's safe and helps people feel better and reach their cholesterol goals.
HypercholesterolemiaPoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo controlled, 2-armmulticenter phase 3 study to assess the efficacy and safetyof ianalumab in patients with active Sjögren’s syndrome(NEPTUNUS-1)
This study is testing a new medicine, ianalumab, for adults with active Sjögren’s syndrome. It compares the new medicine to a dummy medicine (placebo) to see if it helps reduce symptoms and improve quality of life.
Sjögren’s SyndromePoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)
This study is testing a new medicine, AMX0035, for people with Motor Neurone Disease (ALS). It aims to see if the medicine can slow down the disease's progression over 48 weeks, compared to a dummy medicine.
Amyotrophic Lateral Sclerosis (ALS)Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase IIb, Multicentre, Randomised, Double-Blind, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease and Albuminuria
This study is looking at a new drug, balcinrenone, given with an existing drug, dapagliflozin (Forxiga), for people with long-term kidney disease and too much protein in their urine. It aims to see if this new combination helps protect the kidneys.
Chronic Kidney Disease and AlbuminuriaPoland - RecruitingPHASE2
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called brivekimig for moderate to severe hidradenitis suppurativa (HS). It compares brivekimig to a dummy medicine (placebo) to see if it's safe and helps reduce HS symptoms.
Hidradenitis SuppurativaPoland